1992 …2024

Research activity per year

Personal profile

Biography

Position

 

Medicinal Chemistry
Monash Institute of Pharmaceutical Sciences

Research interests

Research in our group has a general focus on Structure-based Design and Synthesis of kinase inhibitors , epigenetic modulators and phosphodiesterase inhibitors. We have particular expertise in Peptides and Peptidomimetics.

Our major current programs deal with

  • isoform selective inhibition of the PI3 kinase family
  • new chemotypes as PDE inhibitors and PDE inhibitors against parasitic diseases
  • polymyxin-based antibacterial agents
  • fluorescent labels for peptides
  • modulators of epigenetic proteins

Monash teaching commitment

B Pharm and B Pharm Sci - 1st Year Bio-organic and Medicinal Chemistry
B Pharm - PAC4441 Integrated therapeutics: Endocrinology and renal
B Pharm Sci - PSC3091 Molecular basis of drug action
B Pharm Sci - PSC3122 Synthetic Medicinal Chemistry

 

 

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Research area keywords

  • Kinase Inhibitors
  • Peptides and Peptidomimetics
  • Structure-Based Design and Synthesis of Kinase
  • Epigenetics

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or